Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule drugs for rare muscular and cardiac diseases. Edgewise has no approved products and generates no revenue; its value rests entirely on its pipeline. The lead program is sevasemten, an oral fast skeletal muscle myosin inhibitor in late-stage trials for Becker muscular dystrophy and Duchenne muscular dystrophy. Sevasemten works by modestly reducing contractile force in the muscle fibers most vulnerable to damage in these diseases, thereby limiting fiber injury with each contraction. Critically, sevasemten's mechanism is mutation-agnostic, meaning it could work across all Becker and Duchenne patients regardless of their specific genetic mutation — unlike most approved Duchenne therapies, which only apply to specific mutation subsets. There are no approved therapies for Becker, so sevasemten would be the first. The second major program is EDG-7500, an oral cardiac sarcomere modulator in Phase 2 for hypertrophic cardiomyopathy. Edgewise argues EDG-7500 can relieve cardiac obstruction without the degree of systolic depression seen with approved cardiac myosin inhibitors, potentially simplifying dosing and enabling use in both obstructive and non-obstructive HCM. A third program, EDG-15400, is in Phase 1 for heart failure with preserved ejection fraction. Edgewise funds development through equity raises, uses CDMOs for manufacturing, and retains global rights to all programs, concentrating both upside and development risk internally.